You are here

Situation Report

Amid signs of improving US coronavius situation, hot spots like Michigan are a warning sign.

 

In a spring of hope, Michigan is a reminder that the Covid winter has yet to pass

Americans have entered a disconcerting phase of the pandemic.

They are awash in hopeful news: With more than 2.8 million shots on average being administered every day, the country is fast approaching universal vaccine eligibility for all adults.

And then there are problems like Michigan.

In a rural stretch of the state along the shore of Lake Huron, coronavirus outbreaks are ripping through churches, schools and restaurants. For more than a week, ambulances have taken several hourlong trips each day to rush Covid-19 patients to I.C.U.s in Detroit, Port Huron or Saginaw.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Europe's vaccine rollout 'unacceptably slow' - WHO

The World Health Organization (WHO) has criticised the rollout of coronavirus vaccines in Europe as being "unacceptably slow".

It also says the situation in the region is more worrying than it has been for several months.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Indications that Vaccines Help Some COVID Long-Haulers

An estimated 10% to 30% of people who get COVID-19 suffer from lingering symptoms of the disease, or what's known as "long COVID."

Judy Dodd, who lives in New York City, is one of them. She spent nearly a year plagued by headaches, shortness of breath, extreme fatigue and problems with smell, among other symptoms.

She says she worried that this "slog through life" was going to be her new normal.

Everything changed after she got her COVID-19 vaccine.

"I was like a new person, it was the craziest thing ever," says Dodd, referring to how many of her health problems subsided significantly after her second shot.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

FDA Approves 2 Rapid COVID Tests for at home use

More consumers will soon be able to test themselves for COVID-19 from the comfort of their own home. On Wednesday, the Food and Drug Administration approved two rapid antigen home tests for use in the U.S.

Americans will soon be able to purchase Abbott's BinaxNOW and Quidel Quickvue tests at drug stores. The two options join a test made by Ellume, which received FDA approval in December, in the market. The two, newly-approved swab tests will be sold at a lower price point.

The BinaxNOW and Quickvue tests are expected to be sold in two-packs for around $15-20; Ellume costs $30.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Situation Report
howdy folks
Page loaded in 1.385 seconds.